Collaborative Arrangements - Molecular Associates Inc (Details) - USD ($)	1 Months Ended					12 Months Ended
	Jul. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Apr. 30, 2021	Jun. 30, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investments in non-marketable securities						$ 5,300,000	$ 7,630,000	$ 2,000,000
Contract liabilities: deferred revenue		$ 6,335,000				30,609,000	6,335,000
Affiliated Entity
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investments in non-marketable securities						0	7,630,000	1,000,000
Contract liabilities: deferred revenue		245,000				$ 0	245,000	0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period						1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period						1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period						1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period						1 year
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period						1 year
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period						1 year
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period						1 year
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Expected timing of satisfaction, period						1 year
MAI
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities: deferred revenue		200,000				$ 0	200,000
MAI | Commercialization And Enzyme Supply Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate commercial sales, milestone					$ 5,000,000
MAI | MAI Agreement | Affiliated Entity
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
MAI agreement milestone payment received	$ 1,000,000
MAI | Master Collaboration & Research Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized from transactions						1,200,000	2,000,000	$ 900,000
MAI | Revenue sharing arrangement | Commercialization And Enzyme Supply Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities: deferred revenue					$ 500,000
MAI | Product revenue | Master Collaboration & Research Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized from transactions						$ 500,000
MAI Agreement | MAI Agreement | Affiliated Entity
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Due from related parties		$ 1,000,000					$ 1,000,000
Series B Preferred Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments received (in shares)						1,587,049
Series B Preferred Stock | MAI | MAI Agreement | Affiliated Entity
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment received (in shares)		1,587,049
Series A and B Preferred Stock | MAI | Master Collaboration & Research Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investment owned, balance (in shares)		3,491,505				1,587,049	3,491,505	714,171
MAI | Series A Preferred Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investment owned, balance (in shares)				1,000,000	1,587,050
Investments in non-marketable securities				$ 600,000	$ 1,000,000
MAI | Series B Preferred Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investment owned, balance (in shares)			9,198,423
Investments in non-marketable securities			$ 7,000,000
MAI | Series A and B Preferred Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Investments in non-marketable securities						$ 13,900,000	$ 12,700,000